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mic ATP-binding site of the receptor TK, lapatinib blocks re-
ceptor phosphorylation and prevents subsequent downstream
signaling. This is in contrast to trastuzumab which acts primar-
ily by stimulating antibody-dependent cellular cytotoxicity
(ADCC) [8, 9]. The rationale for the development of a dual in-
hibitor is threefold: Firstly, the combined blockage of two re-
ceptors involved in tumor proliferation may result in a syner-
gistic inhibition of tumor cell growth [10]. Secondly, the simul-
taneous inhibition of ErbB1 and ErbB2 is thought to be more
effective at preventing the formation of heterodimers contain-
ing ErbB1 and ErbB2 [11]. Finally, this may result in a more
complete inhibition of different signal transduction pathways
of the partly redundant intracellular signaling network [12]. 
Lapatinib may overcome trastuzumab resistance linked to the
overexpression of a truncated form of ErbB2 (p95) which can
be detected in an estimated 9% of breast cancer cells [13].
This truncated version lacks the extracellular receptor domain
so that trastuzumab is unable to bind to the cancer cells. The
membrane-associated p95 fragment shows high kinase activity
in vitro and is characterized by an increased transforming po-
tency and a worse outcome [5, 13, 14]. 
Another mechanism conferring resistance to trastuzumab
therapy is loss of the tumor suppressor gene PTEN (phos-
phatase and tensin homologue deleted on chromosome 10),
which occurs in about 50% of all breast cancers and correlates
with a high potential of invasion and poorer prognosis. Signif-
icant loss of PTEN expression is seen in some 20–25% of
HER2-positive breast cancers [15–18]. Activating mutations
in PIK3CA have also been found in approximately 25% of
primary breast cancers, and these mutations occur almost ex-
clusively in PTEN-positive samples [17, 18]. Since both the
loss of PTEN and oncogenic mutations in PIK3CA lead to ac-
tivation of PI3K/AKT signaling [19], one would expect that
both genes can contribute to the prediction of response to
trastuzumab. Trastuzumab partially works by activating
The ErbB Family – a New Target for Breast Cancer
 Therapy
The members of the family of ErbB receptors (ErbB1–4) play
an essential role in cell proliferation and survival. Their over-
expression or mutation is a common feature in a large variety
of human cancers and linked with poor response to therapy
and shorter survival times. Nevertheless, overexpressed or mu-
tated receptors may still be responsive to regulation, and their
inhibition eventually leads to reduced proliferation, induction
of apoptosis in tumor cells, and a regression of metastases
[1–5]. The 4 ErbB receptors are structurally well conserved
and consist of an extracellular domain responsible for ligand
binding, a helical transmembrane region, and an intracellular
protein tyrosine kinase (TK) domain [6]. When activated by
ligand binding, homodimerization or heterodimerization of
these receptors occurs, resulting in autophosphorylation and
finally activation of different signal transduction pathways
within the cell [1]. 
As ErbB1 (epidermal growth factor receptor, EGFR) is over-
expressed in about one third of breast cancers and overex-
pression of ErbB2 (HER2) occurs in 20–25% of these tumors,
ErbB-targeting therapies emerged as an attractive treatment
modality for breast cancer [7]. The first agent developed to
target ErbB2 was the monoclonal antibody trastuzumab, tar-
geting the extracelluar ErbB2 domain. An alternative ap-
proach is the development of small molecules which penetrate
the cell membrane and block the intracellular TK activity by
competitive inhibition. 
Lapatinib: Molecular Profile and Mechanism of Action
Lapatinib as a small molecule is the first oral, dual inhibitor of
both ErbB1 and ErbB2. By reversibly binding to the cytoplas-
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PTEN, which in turn leads to an inhibition of downstream sig-
naling. PTEN deficiency was identified as a predictive marker
for resistance to the monoclonal antibody in vitro, in vivo, and
in the clinical setting [16]. Evidence that lapatinib may over-
come this resistance comes from a neoadjuvant trial in pa-
tients with inflammatory breast cancer (IBC): After 8 weeks
of lapatinib monotherapy, a high response rate was reported
even in patients with PTEN deficiency or low PTEN expres-
sion [20].
Lapatinib peak plasma levels occur 3–6 h after oral adminis-
tration. The effective plasma half-life is approximately 24 h.
The elimination of lapatinib occurs through hepatic metabo-
lism, primarily through cytochrome P450 (CYP)3A4 and ex-
cretion in the feces. Therefore, inducers and inhibitors of
CYP3A4 may alter the metabolism of lapatinib. Given the sig-
nificance of CYP3A4 in drug metabolism, lapatinib should be
used with caution when dosed concurrently with medications
that are substrates, inhibitors, or inducers of CYP3A4. Addi-
tionally, antacids that modify gastric pH may affect absorption
of lapatinib and should generally be avoided for 1 h before
and after lapatinib dosing. Lapatinib should also be used with
great caution in patients with severe hepatic dysfunction [21].
Moreover, lapatinib potentially interacts with warfarin and
quinazoline derivatives to increase the international normal-
ized ratio (INR) and bleeding. Lastly, lapatinib should not be
taken with grapefruit or grapefruit juice. Table 1 lists the po-
tential drug-drug interactions with lapatinib.
Early Clinical Data with Lapatinib
Phase I studies designed to determine the feasibility, safety,
and efficacy of lapatinib gave a strong positive signal for the
activity of this dual TK inhibitor in heavily pretreated patients
with solid tumors overexpressing ErbB1 and/or ErbB2. Four
partial remissions with a response duration of 3–8 months
were seen in patients with ErbB2-positive breast cancer after
failure of trastuzumab, with lapatinib in doses ranging from
650 to 1,200 mg/day [22]. The most frequently reported drug-
related adverse events (grade 1–4) were diarrhea in 42%, rash
in 31%, nausea in 13%, and fatigue in 10% of patients. Only 4
of the total 67 patients experienced a grade 3 adverse event,
and there were no grade 4 events. 
In the phase I trial EGF 10023 in 54 pretreated and trastuzu -
mab-resistant patients, the combination of lapatinib in doses
ranging from 750 to 1,500 mg daily with trastuzumab resulted
in 1 complete and 7 partial remissions, as well as long lasting
stabilizations in a further 11 patients [23]. The trial defined an
CYP3A4 inhibition CYP3A4 induction 
Lapatinib concentration ↑ Lapatinib concentration ↓
Antibiotics antibiotics
telithromycin, clarithromycin, erythromycin rifampicin, rifabutin, rifapentine
Antifungals anitconvulsants
itraconazole, ketoconazole, phenytoin, carbamazepine, 
fluconazole (>150 mg daily), voriconazole barbiturates (phenobarbital)
Antiretrovirals antiretrovirals 
delaviridine, nelfinavir, amprenavir, ritonavir, efavirenz, nevirapine
indinavir, saquinavir, lopinivir
Antidepressants oral glucocorticoids*
nefazodone, fluvoxamine chronic use of cortisone (>50 mg),  
hydrocortisone (>40 mg), prednisone 
(>10 mg), methylprednisolone (>8 mg), 
dexamethasone (>1.5 mg) 
GI agents herbal agents
cimetidine, aprepitant St John’s wort
Other other
amiodarone modafinil
Antacids
magnesium and aluminumhydroxide, 
simethicone, calciumcarbonate, 
magnesiumcarbonate
Fruit / herbal agents 
grapefruit, grapefruit juice, Ginkgo biloba, 
kava, grape seeds, valerian, echniacea, 
Oenothera biennis (oil)
* Premedication before paclitaxel, oral glucocorticoids of ≤1.5 mg dexamethasone (or equivalent)
and short-term use of steroids (up to 2 weeks) permitted.
Table 1. Lapatinib: Potential drug-drug
 interactions
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optimally tolerated regimen with lapatinib at a dose of 1,000
mg per day and trastuzumab at the standard dose. The most
common adverse events were diarrhea, rash, fatigue, nausea,
vomiting, and anorexia without an increase in incidence com-
pared to the monotherapies. The simultaneous application of
both anti-ErbB2 therapies did not change the pharmacokinet-
ic properties of either drug. Based on these data and positive
results concerning efficacy and safety in several other trials in
which lapatinib was examined in combination with cytotoxics
such as paclitaxel, docetaxel, or capecitabine, the clinical de-
velopment of the dual TK inhibitor has been continued.
Clinical Phase II Studies with Lapatinib
In the phase II EGF 20009 trial, lapatinib (1,500 mg sid or 500
mg bid) as first-line monotherapy induced partial responses in
24% and disease stabilization in 51% of 138 patients with lo-
cally advanced or metastatic ErbB2-positive (as determined
by fluorescent in situ hybridization (FISH)) breast cancer [24].
These findings of overall anti-tumor efficacy are comparable
with response rates reported for trastuzumab as first-line
monotherapy in ErbB2-positive metastatic breast cancer [25].
Moreover, EGF 20009 was the first study reporting activity of
lapatinib against brain metastases. 
In most women with metastatic ErbB2-overexpressing breast
cancer treated with trastuzumab, the tumor will eventually de-
velop resistance to this monoclonal antibody. Therefore, two
phase II trials (EGF 20002, EGF 20008) evaluated lapatinib
monotherapy as an alternative anti-ErbB2 therapy in ErbB2-
positive breast cancer after trastuzumab failure [26]. These
studies confirmed the activity of this dual TK inhibitor in pa-
tients with disease progression after trastuzumab-containing
regimens already reported in the early phase I trials [23].
EGF100151 Pivotal Trial and Other Phase III Trials
The evaluation of lapatinib in combination with capecitabine
in the pivotal EGF 100151 trial was based on the encouraging
results of Schwartz et al. [28] who reported the clinical activity
of this regimen and an adverse event profile similar to that of
the single agents. The phase III trial compared capecitabine 
at the standard dose (2,500 mg/m2 daily over 14 days every 
3 weeks) with the combination of capecitabine (2,000 mg/m2
daily over 14 days every 3 weeks) and lapatinib (1,250 mg
daily; fig. 1) [29]. Eligible for the study were patients with
ErbB2-positive, locally advanced or metastatic breast cancer
who had progressed after treatment with anthracyclines, tax-
anes, and trastuzumab [29]. Treatment was given until progres-
sion of disease or manifestation of intolerable adverse events.
Both arms were well balanced in terms of patient and disease
characteristics. The primary endpoint of the trial was time to
progression (TTP), secondary endpoints were progression-free
survival, overall survival, overall response rate, and safety.
At the time of the first interim analysis, the primary endpoint
TTP met the pre-specified criteria for early reporting on the
basis of superiority of the combination arm. The independent
Data and Safety Monitoring Committee therefore recom-
mended termination of enrollment [29]. In total, 399 patients
had been recruited, and 198 women had been randomly as-
signed to the combination of capecitabine and lapatinib, 201 
to capecitabine only.
In the updated analysis reported by Cameron et al. [30], 47 pa-
tients in the combination arm (23.7%) and 28 patients in the
capecitabine alone arm (13.9%) showed a clinical response (p
= 0.017). With 82 events in the combination arm compared to
102 events in the capecitabine alone arm, there was a clinically
meaningful and significant advantage favoring the combina-
tion treatment with a hazard ratio of 0.57 (p = 0.00013). Medi-
an TTP was 6.2 months for patients receiving capecitabine
plus lapatinib, compared to 4.3 months for patients treated by
capecitabine monotherapy (fig. 2). Overall survival as a sec-
Fig. 1. Design of the phase III study EGF 100151 [29]. Randomized as of
April 3, 2006 n = 399. Patients on treatment until progression or unac-
ceptable toxicity, then followed for survival.
Key Inclusion:
• Progressive, HER2+ 
(IHC 3+ or IHC 2+ and 
FISH +) MBC or LABC 
• Previously treated with 
anthracycline,  taxane 
and trastuzumab 
• No prior capecitabine
• Measurable disease by 
RECIST
• LVEF  institution LLN 
Lapatinib 1250 mg po 
qd continuously + 
Capecitabine 2000 mg/m2/d 
po days 1-14 q 3 wk 
Capecitabine 2500 mg/m2/d 
po days 1-14 q 3 wk
Stratification:
• Disease sites
• Stage of disease
Endpoints:
• Primary: TTP
• Secondary: PFS, OS, 
RR, safety
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Fig. 2. Phase III study EGF 100151: time to progression (ITT popula-
tion) and event-free survival (ITT population) [29]. Clinical outcome data
for 399 randomized patients.
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ondary endpoint was comparable in both arms with 15.6
months for lapatinib plus capecitabine and 15.3 months for
capecitabine as monotherapy (fig. 2). Despite EGF 100151
being powered to show a significant survival benefit for the
combination, after the study had been stopped early, a signifi-
cant difference could not be observed at the time of analysis
due to a lack of required events. The survival improvement in-
creased over time from the pre-planned interim analysis to the
updated analysis 5 months later with the respective hazard
rates of 0.92 and 0.78 [29, 30]. 
The significant improvement in efficacy by combining
capecitabine with lapatinib was achieved without a significant
increase in serious toxicities or cardiotoxic events. In 5 pa-
tients (4 in the combination arm, 1 in the capecitabine arm),
an asymptomatic decrease of the left ventricular ejection frac-
tion (LVEF) was reported but did not lead to discontinuation
of treatment. On the basis of these results, the authors con-
cluded that lapatinib in combination with capecitabine is an
effective new regimen in ErbB2-positive breast cancer and
can be regarded as a new treatment standard after failure of
trastuzumab [29]. For this reason, the treatment with lapatinib
in combination with capecitabine for trastuzumab failure after
pretreatment with anthracyclines and taxanes was incorporat-
ed in the national treatment guidelines of the AGO (Arbeits-
gemeinschaft Gynäkologische Onkologie) [31].
A second phase III study (EGF30001) evaluated lapatinib
(1,500 mg daily) in combination with paclitaxel (175 mg/m2
every 3 weeks) versus paclitaxel alone in 579 patients with ad-
vanced or metastatic breast cancer in the first-line setting [32].
Patients were untested or negative for ErbB2. The primary
endpoint was TTP. This study revealed a differential treatment
effect in ErbB2-negative and ErbB2-positive patients. In the
total study population as well as in the ErbB2-negative cohort
(n = 401), both treatments were equally active in terms of the
primary endpoint TTP. In contrast, in patients with tumors
tested ErbB2-positive in the predefined central analysis, the
combination of lapatinib and paclitaxel was superior to pacli-
taxel alone: women in the combination arm had a median TTP
of 7.9 months compared to only 5.2 months for the paclitaxel-
treated women (p = 0.0007; hazard ratio: 0.56). There was a
trend in overall survival favoring the combination treatment
with 24 months versus 19 months for the paclitaxel alone arm
(p = 0.160). This result is comparable to data from Slamon et
al. [33] who compared trastuzumab plus paclitaxel versus pa-
clitaxel only and reported a median overall survival of 25 ver-
sus 18 months. Other efficacy parameters, such as TTP, re-
sponse rate, and median duration of response, are also within
the same range. 
Activity of Lapatinib against Brain Metastases
The treatment of patients with advanced breast cancer devel-
oping metastases in the central nervous system (CNS) contin-
ues to be a challenge. In women with ErbB2-positive breast
cancer, the estimated incidence of brain metastases is about
30% [34–36]. Possible reasons for this observed increased inci-
dence of brain metastases include: i) more effective systemic
treatments resulting in a longer overall survival; ii) more sen-
sitive diagnostic tools, e.g. dynamic contrast enhanced magnet-
ic resonance imaging (MRI); and iii) an increased awareness
of this problem in patients and physicians. 
Young age (premenopausal status), negative hormone recep-
tor status, and infiltrating ductal carcinoma histology were
identified as risk factors associated with the development of
CNS metastases in a multivariate analysis [37]. The 1-year sur-
vival rate for breast cancer patients with brain metastases is
about 25%, and median survival is shorter in patients with
ErbB2-positive disease compared to ErbB2-negative disease
[37]. As the blood-brain barrier shows permeability for lipid-
soluble substances below a molecular weight of 400 Da via
lipid-mediated free diffusion, the monoclonal antibody
trastuzumab (molecular weight: 148 kD) is unable to pene-
trate into the CNS under physiologic circumstances [27].
Clearly therefore, drugs which have the potential to penetrate
the blood-brain barrier and target ErbB2-overexpressing
metastases in the CNS are urgently needed. In an exploratory
analysis of the pivotal trial EGF 100151, the frequency of
brain metastases as site of first progression was significantly
lower in the combination group of lapatinib and capecitabine
than in the capecitabine alone arm (4 (8%) vs. 13 (6%); p
value = 0.045) [30]. 
The activity of lapatinib against brain metastases was further
evaluated in a study presented by Lin et al. [38]. In this study,
241 patients with radiologically documented progressive brain
metastases after prior cranial irradiation and trastuzumab
therapy received lapatinib (750 mg bid) single agent therapy.
In the case of progressive disease, patients continued to an ex-
tension arm and received a combination of lapatinib with
capecitabine. The majority of patients (87%) presented with
CNS metastases and systemic disease. Fifteen patients (6%)
responded to lapatinib with a partial regression of brain
metastases, 102 patients (42%) with disease stabilization. In
an exploratory analysis, 19 patients (7%) experienced durable
volumetric reductions of the CNS disease of at least 50% with
a median absolute volumetric reduction of 3.1 cm³. A total of
46 patients (19%) experienced a volumetric reduction of at
least 20% (absolute tumor reduction: 1.9 cm³). The median
progression-free survival for the whole study population was
15.1 weeks. In lapatinib responders this interval was prolonged
to a median of 25.3 weeks. Forty patients in the extension arm
received the combined treatment of lapatinib and capecita -
bine. Here, a volumetric reduction of at least 50% was ob-
served in 8 patients (20%) and of at least 20% in 16 patients
(40%; table 2). Based on these interesting results, the combi-
nation of lapatinib plus capecitabine can be regarded as a
promising new approach to treating CNS disease in ErbB2-
positive breast cancer. Clearly, further evaluation of lapatinib
10 Breast Care 2008;3(suppl 1):7–12 Harbeck/Heinemann/Loibl/Untch
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in combination with other cytotoxic drugs and radiotherapy is
warranted. 
In the ongoing phase II EGF 107671 trial, the combination of
lapatinib and capecitabine will be compared to lapatinib plus
topotecan in patients with ErbB2-overxpressing metastatic
breast cancer after prior irradiation and trastuzumab-based
therapy. A German phase I/II trial will explore a combined
modality treatment of radiotherapy plus lapatinib and cape-
citabine in patients with ErbB2-overexpressing breast cancer
and at least 2 newly diagnosed brain metastases (R. Fietkau,
personal communication). Ongoing neoadjuvant and adjuvant
trials (Neo-ALTTO and ALTTO) with lapatinib will show
whether prevention of CNS disease is achievable by early
treatment with this small molecule. 
Lapatinib in the Treatment of Inflammatory Breast
 Cancer
With an incidence of only 1–6%, inflammatory breast cancer
(IBC) is a relatively rare disease. IBC is diagnosed clinically,
affected women report with redness, induration, pain, and a
sudden onset of symptoms. Before the introduction of sys-
temic therapy, patients with IBC had a poor prognosis with an
overall survival at 5 years of less than 5%. Since 1990, more
aggressive treatment approaches with systemic therapies and
higher rates of mastectomy have improved outcome with a
significant prolongation of recurrence-free survival (p = 0.01),
but without increase in overall survival [39]. Of crucial impor-
tance for this moderate improvement was the introduction of
modern cytotoxic regimens with anthracyclines and taxanes as
well as dose-dense chemo therapy. Thus, primary systemic
treatment before surgery is nowadays considered the standard
for IBC. 
Nevertheless, the outcome of patients with this disease is still
poor, and additional treatment approaches are urgently need-
ed. As IBC is characterized by overexpression of ErbB1 in
about 30% and of ErbB2 in 40% of cases, therapy with lapa-
tinib would be a logical strategy. First results of phase I studies
showed that lapatinib can induce responses in heavily pre-
treated women with inflammatory ErbB1/ErbB2-positive
breast cancer after failure of trastuzumab [40]. Based on these
encouraging results, single-drug lapatinib was evaluated in the
phase II EGF 103009 study in 49 patients with anthracyclin-re-
fractory IBC with or without ErbB2 overexpression [41]. In
the ErbB2-negative cohort, 8.3% of patients responded to lap-
atinib with a partial response and 17% with a stabilization of
the disease. In patients with ErbB2-overexpressing tumors, la-
patinib showed a much higher activity and induced partial re-
sponses in 62% and disease stabilization in 21% of the pa-
tients. 69% of these responders had tumors with PTEN defi-
ciency which is thought to be associated with resistance to
trastuzumab. 
In the phase II EGF 102580 study, lapatinib in combination
with paclitaxel was evaluated as neoadjuvant therapy in
women with or without ErbB2-overexpressing primary IBC
[42]. Patients were treated for 2 weeks by lapatinib as mono -
therapy. After a tumor biopsy on day 14, lapatinib was com-
bined with paclitaxel, and the treatment continued for another
12 weeks until surgery. In the cohort of patients with ErbB2-
overexpressing tumors (n = 30), the combined neoadjuvant
treatment induced complete responses in 3 (10%) and partial
responses in 20 (67%) patients. Moreover, 10 patients (30%)
in this cohort had already responded to lapatinib as monother-
apy. The rate of pathological complete remissions was 17%.
Four of the 5 patients in cohort B with ErbB2-negative tumors
had a partial response, but there were no complete and patho-
logical complete remissions. In the biomarker analysis, phos-
phorylated ErbB2 was identified as a predictor of response to
lapatinib therapy. 
A phase III study (EGF108838) with lapatinib in patients with
recurrent IBC with ErbB2 overexpression is ongoing. In this
trial, lapatinib as single drug is compared to the combination
of lapatinib with pazopanib, a multi-TK inhibitor of vascular
endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) receptors. The primary endpoint is pro-
gression-free survival. 
In conclusion, based on the encouraging data of several phase
II and phase III trials, lapatinib appears to be a promising new
treatment for ErbB2-positive breast cancer patients who have
progressed on trastuzumab. Based on the data of the phase III
trial with lapatinib in combination with capecitabine, lapatinib
was licensed by the FDA in the US in March 2007 and re-
ceived a positive opinion by the EMEA in December 2007.
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